Vertex Q2 revenue $3.33B (+12% YoY); raises FY revenue guidance to $13.1-13.2B; announces $10B Crinetics acquisition

VERTEX PHARMACEUTICALS INC / MA

Total revenue $3.33B, up 12% YoY; GAAP net income $1.1B, non-GAAP $1.2B.
Full-year 2026 revenue guidance raised to $13.1-13.2B from $12.95-13.1B.
CASGEVY revenue $76M (+151% YoY); JOURNAVX revenue $50M (quadrupled YoY).
Entered agreement to acquire Crinetics for $85/share, total equity value ~$10B; close expected Q3 2026.
Povetacicept PDUFA date Nov 30, 2026 for IgAN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.